Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Portland, Oregon

This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9364
Shown on this page
12
Current sort
Recently updated
Location scope
Portland, OR
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Portland, Oregon. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 361–372 of 9,364 matching trials in Portland, OR.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting No phase listed Observational

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

NCT07335523
View directory record Official record
Conditions
Exocrine Pancreatic Insuficiency
Interventions
Fecal Fat
Diagnostic Test
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
7 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Body and the Brain: Cortical Reactivity and Cognitive-Affective Regulation to Experimental Pain.

NCT07896785
View directory record Official record
Conditions
Nonspecific Chronic Low Back Pain
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394
View directory record Official record
Conditions
Dravet Syndrome
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Suspended Phase 2Phase 3 Interventional

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

NCT05691478
View directory record Official record
Conditions
High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Interventions
Bone Scan, Cabozantinib S-malate, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Surgical Procedure, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 40 Years
Enrollment
1,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
181
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting No phase listed Observational

Cardiogenic Shock Working Group Registry

NCT04682483
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Vasopressor, Inotrope, Acute Mechanical Circulatory Support Devices
Drug · Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Weston, Florida • Chicago, Illinois • Portland, Maine + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Completed Phase 2 Interventional

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

NCT05230537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
22
States / cities
Fullerton, California • Huntington Beach, California • Rancho Cordova, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting No phase listed Observational

CCM OPEN HF Registry

NCT07112924
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
5,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
30
States / cities
Mesa, Arizona • Phoenix, Arizona • Surprise, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy

NCT01382082
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Not listed
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
21 Years and older
Enrollment
1,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
29
States / cities
Newark, Delaware • Decatur, Illinois • Prairie Village, Kansas + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting Not applicable Interventional

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)

NCT07216872
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism, Alcohol Abuse, Alcohol Dependence, Alcohol Abuse/Dependence, Alcohol Addiction
Interventions
Deep TMS (DTMS), Sham (No Treatment)
Device
Lead sponsor
Brainsway
Industry
Eligibility
18 Years to 86 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Tuscaloosa, Alabama • La Jolla, California • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting Phase 2 Interventional

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 10:43 AM EST